{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T17:28:38Z","timestamp":1763486918988,"version":"3.45.0"},"reference-count":28,"publisher":"CSIRO Publishing","issue":"3","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":210,"URL":"https:\/\/doi.org\/10.1071\/journalslicense"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tenofovir disoproxil-containing HIV pre-exposure prophylaxis (PrEP) is associated with a small risk of renal impairment. How this risk may differ in Aboriginal and Torres Strait Islander peoples (hereafter, respectfully, \u2018Indigenous\u2019) who have higher rates of chronic kidney disease and associated risk factors than non-Indigenous Australians, has yet to be described.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective longitudinal open cohort study of adults with a baseline estimated glomerular filtration rate (eGFR) \u226560\u00a0mL\/min\/1.73\u00a0m2 commencing tenofovir disoproxil-containing PrEP as part of routine care was conducted. Client data were collected from 67 clinics participating in the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance of Sexually Transmissible Infections and Blood Borne Viruses network between January 2012 and December 2019. The primary outcome was the rate of new renal impairment, defined as an eGFR of &amp;lt;60\u00a0mL\/min\/1.73\u00a0m2 or &amp;gt;25% decline of eGFR from baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 8696 adults, 203 identified as Indigenous and were eligible for inclusion. The median age was 34\u00a0years (IQR 28\u201344), 96.8% were men who have sex with men and 90.1% resided in major cities. Indigenous clients were less likely to have a baseline eGFR 60\u201390\u00a0mL\/min\/1.73\u00a0m2 (15.8% vs 24.1%; P\u00a0=\u00a00.006). Over a median follow-up period of 1.7\u00a0years (IQR 1.1\u20132.4), rates of renal impairment were similar for Indigenous and non-Indigenous clients: 5.6 events\/1000 person-years (95% CI 1.4\u201322.8) and 4.8 events\/1000 person-years (95% CI 3.9\u20136.1) respectively (P\u00a0=\u00a00.83).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Renal impairment was rare among Australians commencing PrEP as part of usual care. We observed no difference in the development of renal impairment among Indigenous and non-Indigenous Australians.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1071\/sh24149","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T19:12:04Z","timestamp":1745262724000},"source":"Crossref","is-referenced-by-count":0,"title":["Renal impairment risk in Indigenous and non-Indigenous people who take HIV pre-exposure prophylaxis (PrEP): a retrospective cohort study"],"prefix":"10.1071","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6900-2029","authenticated-orcid":true,"given":"D.","family":"Drak","sequence":"first","affiliation":[{"name":"ACentral Clinical School, University of Sydney, Camperdown, NSW, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"McManus","sequence":"additional","affiliation":[{"name":"BKirby Institute, UNSW Sydney, Sydney, NSW, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Vickers","sequence":"additional","affiliation":[{"name":"BKirby Institute, UNSW Sydney, Sydney, NSW, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Salerno","sequence":"additional","affiliation":[{"name":"CHealth Equity Matters, Surry Hills, NSW, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Tobin","sequence":"additional","affiliation":[{"name":"DPositive Life NSW, Surry Hills, NSW, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. T.","family":"Hughes","sequence":"additional","affiliation":[{"name":"EDivision of Medicine, Royal Darwin Hospital, Darwin, NT, Australia."},{"name":"FFlinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Darwin, NT, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. A.","family":"Lewis","sequence":"additional","affiliation":[{"name":"GWestern Sydney Sexual Health Centre, Parramatta, NSW, Australia."},{"name":"HWestmead Clinical School, Faculty of Medicine and Health and Sydney Institute for Infectious Diseases, University of Sydney, Westmead, NSW, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2151-2622","authenticated-orcid":true,"given":"A.","family":"Carter","sequence":"additional","affiliation":[{"name":"BKirby Institute, UNSW Sydney, Sydney, NSW, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Russell","sequence":"additional","affiliation":[{"name":"ICairns Sexual Health Service, Cairns North, Qld, Australia."},{"name":"JJames Cook University, Townsville, Qld, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Gunathilake","sequence":"additional","affiliation":[{"name":"KSexual Health & Blood Borne Virus Unit of Centre for Disease Control, Northern Territory Department of Health, Tiwi, NT, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Ali","sequence":"additional","affiliation":[{"name":"LThe University of Queensland, St Lucia, Qld, Australia."},{"name":"MBrown University, Providence, RI, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Guy","sequence":"additional","affiliation":[{"name":"BKirby Institute, UNSW Sydney, Sydney, NSW, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. C.","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"BKirby Institute, UNSW Sydney, Sydney, NSW, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Ward","sequence":"additional","affiliation":[{"name":"NPoche Centre for Indigenous Health, The University of Queensland, Herston, Qld, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. M.","family":"Gracey","sequence":"additional","affiliation":[{"name":"ACentral Clinical School, University of Sydney, Camperdown, NSW, Australia."},{"name":"ODepartment of Renal Medicine, Royal Prince Alfred Hospital, Camperdown, NSW, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of ACCESS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"67","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"issue":"11","key":"2025111812245434300_R1","doi-asserted-by":"publisher","first-page":"e629","DOI":"10.1016\/s2352-3018(18)30215-7","article-title":"Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study.","volume":"5","author":"Grulich","year":"2018","journal-title":"Lancet HIV"},{"issue":"10013","key":"2025111812245434300_R2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/s0140-6736(15)00056-2","article-title":"Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.","volume":"387","author":"McCormack","year":"2016","journal-title":"Lancet"},{"key":"2025111812245434300_R3","unstructured":"The Australian Society for HIV Viral Hepatitis and Sexual Health Medicine. National PrEP Guidelines Update. Prevent HIV by Prescribing PrEP. Sydney: The Australian Society for HIV Viral Hepatitis and Sexual Health Medicine; 2021."},{"key":"2025111812245434300_R4","unstructured":"The Kirby Institute. Monitoring HIV pre-exposure prophylaxis (PrEP) uptake in Australia. (Issue 7); 2022. Available at https:\/\/www.kirby.unsw.edu.au\/sites\/default\/files\/documents\/Monitoring-HIV-PrEP-uptake-in-Australia-newsletter_Issue7.pdf"},{"key":"2025111812245434300_R5","unstructured":"Australian Government \u2013 Department of Health and Aged Care. The Pharmaceutical Benefits Scheme; 2023. Available at www.pbs.gov.au"},{"issue":"11","key":"2025111812245434300_R6","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1016\/s2352-3018(16)30153-9","article-title":"Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study.","volume":"3","author":"Gandhi","year":"2016","journal-title":"Lancet HIV"},{"issue":"2","key":"2025111812245434300_R7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/qai.0000000000001566","article-title":"Changes in kidney function associated with daily tenofovir disoproxil fumarate\/emtricitabine for HIV preexposure prophylaxis use in the United States demonstration project.","volume":"77","author":"Tang","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"14","key":"2025111812245434300_R8","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1097\/qad.0000000000003035","article-title":"Renal impairment in a large-scale HIV preexposure prophylaxis implementation cohort.","volume":"35","author":"Drak","year":"2021","journal-title":"AIDS"},{"issue":"5","key":"2025111812245434300_R9","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1053\/j.ajkd.2011.01.022","article-title":"Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence.","volume":"57","author":"Hall","year":"2011","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2025111812245434300_R10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.5694\/j.1326-5377.2001.tb143507.x","article-title":"Regional variation in the incidence of end-stage renal disease in Indigenous Australians.","volume":"175","author":"Cass","year":"2001","journal-title":"Med J Aust"},{"key":"2025111812245434300_R11","unstructured":"Australian Institute of Health and Welfare. Cardiovascular disease, diabetes and chronic kidney disease \u2014 Australian facts: Aboriginal and Torres Strait Islander people. Canberra: Australian Institute of Health and Welfare; 2015."},{"issue":"5","key":"2025111812245434300_R12","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1097\/qai.0000000000001129","article-title":"Preexposure prophylaxis for HIV prevention in a large integrated health care system: adherence, renal safety, and discontinuation.","volume":"73","author":"Marcus","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025111812245434300_R13","first-page":"1","article-title":"Review of kidney disease among Indigenous people.","volume":"13","author":"Stumpers","year":"2013","journal-title":"Aust Indig Health Bull"},{"issue":"9","key":"2025111812245434300_R14","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/j.1440-1754.2010.01851.x","article-title":"The burden of kidney disease in Indigenous children of Australia and New Zealand, epidemiology, antecedent factors and progression to chronic kidney disease.","volume":"46","author":"White","year":"2010","journal-title":"J Paediatr Child Health"},{"issue":"3","key":"2025111812245434300_R15","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1071\/sh07011","article-title":"A new surveillance system for monitoring HIV infection in Victoria, Australia.","volume":"4","author":"Guy","year":"2007","journal-title":"Sex Health"},{"issue":"11","key":"2025111812245434300_R16","doi-asserted-by":"publisher","DOI":"10.2196\/11028","article-title":"Monitoring the control of sexually transmissible infections and blood-borne viruses: protocol for the Australian collaboration for coordinated enhanced sentinel surveillance (ACCESS).","volume":"7","author":"Callander","year":"2018","journal-title":"JMIR Res Protoc"},{"issue":"1","key":"2025111812245434300_R17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ki.2010.483","article-title":"The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report.","volume":"80","author":"Levey","year":"2011","journal-title":"Kidney Int"},{"key":"2025111812245434300_R18","unstructured":"Australian Bureau of Statistics. National Aboriginal and Torres Strait Islander Health Survey Canberra; 2019. Available at https:\/\/www.abs.gov.au\/statistics\/people\/aboriginal-and-torres-strait-islander-peoples\/national-aboriginal-and-torres-strait-islander-health-survey\/latest-release"},{"key":"2025111812245434300_R19","unstructured":"Australian Institute of Health and Welfare. Profile of First Nations people. Canberra: AIHW; 2023."},{"issue":"1","key":"2025111812245434300_R20","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/1753-6405.12852","article-title":"\u201cNo-one\u2019s driving this bus\u201d \u2013 qualitative analysis of PrEP health promotion for Aboriginal and Torres Strait Islander gay and bisexual men.","volume":"43","author":"Hope","year":"2019","journal-title":"Aust N Z J Public Health"},{"issue":"2","key":"2025111812245434300_R21","doi-asserted-by":"publisher","first-page":"64","DOI":"10.5694\/mja2.52181","article-title":"Rationale and plan for a focus on First Nations urban health research in Australia.","volume":"220","author":"Stajic","year":"2024","journal-title":"Med J Aust"},{"issue":"1","key":"2025111812245434300_R22","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1016\/s2352-3018(15)00211-8","article-title":"Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.","volume":"3","author":"Mocroft","year":"2016","journal-title":"Lancet HIV"},{"issue":"2","key":"2025111812245434300_R23","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25252","article-title":"Persistence on HIV preexposure prophylaxis medication over a 2-year period among a national sample of 7148 PrEP users, United States, 2015 to 2017.","volume":"22","author":"Coy","year":"2019","journal-title":"J Int AIDS Soc"},{"issue":"23","key":"2025111812245434300_R24","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","article-title":"On-demand preexposure prophylaxis in men at high risk for HIV-1 infection.","volume":"373","author":"Molina","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"2025111812245434300_R25","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S2055-6640(20)30260-0","article-title":"Australasian society for HIV, viral hepatitis and sexual health medicine HIV pre-exposure prophylaxis: clinical guidelines.","volume":"4","author":"Wright","year":"2018","journal-title":"J Virus Erad"},{"issue":"5","key":"2025111812245434300_R26","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1097\/qad.0000000000002456","article-title":"HIV preexposure prophylaxis with tenofovir disoproxil fumarate\/emtricitabine and changes in kidney function and tubular health.","volume":"34","author":"Ascher","year":"2020","journal-title":"AIDS"},{"issue":"4","key":"2025111812245434300_R27","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1097\/QAI.0000000000000868","article-title":"Reversibility of glomerular renal function decline in HIV-uninfected men and women discontinuing emtricitabine-tenofovir disoproxil fumarate pre-exposure prophylaxis.","volume":"71","author":"Mugwanya","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"2025111812245434300_R28","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/qad.0b013e32835883bf","article-title":"Tenofovir-associated proteinuria.","volume":"27","author":"Kelly","year":"2013","journal-title":"AIDS"}],"container-title":["Sexual Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/connectsci.au\/sh\/article-pdf\/doi\/10.1071\/SH24149\/1359645\/sh24149.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/connectsci.au\/sh\/article-pdf\/doi\/10.1071\/SH24149\/1359645\/sh24149.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T17:24:59Z","timestamp":1763486699000},"score":1,"resource":{"primary":{"URL":"https:\/\/connectsci.au\/sh\/article\/22\/3\/SH24149\/199811\/Renal-impairment-risk-in-Indigenous-and-non"}},"subtitle":[],"editor":[{"given":"Cheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6,10]]}},"URL":"https:\/\/doi.org\/10.1071\/sh24149","relation":{},"ISSN":["1448-5028","1449-8987"],"issn-type":[{"type":"print","value":"1448-5028"},{"type":"electronic","value":"1449-8987"}],"subject":[],"published":{"date-parts":[[2025,4,22]]},"article-number":"SH24149"}}